Clinical Trial Update: A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating pasritamig versus placebo in late-line metastatic castration-resistant prostate cancer is currently recruiting. Sponsored by Janssen Re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pasritamig

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Metastatic Castration-resistant Prostate Neoplasms | Phase 3 | Status: RECRUITING